Medtronic Plc (MDT) faces both encouraging and negative market sentiments. Jim Cramer states that MDT may post better than expected figures. Several significant investment firms, including QRG Capital Management and Manning & Napier Advisors, have hefty stock holdings in MDT, and several others like Bogart Wealth and MGO One Seven have made substantial share purchases. The company's Chairman and CEO Geoff Martha recently spoke at the J.P. Morgan healthcare conference, hinting at possible future moves. Yet, contrary to this, MDT shows stock performance compared to other medical device stocks. Despite the firm's earnings call highlights showing strong revenue and EPS growth, the company has some bearish options activity. However, Medtronic has listed its Diabetes business, MiniMed, for an IPO and received FDA approval for its SmartGuard Algorithm as an automated glycemic controller. Analysts also give MDT a 'moderate buy' rating, acknowledging the opportunity for future growth.
Medtronic Plc MDT News Analytics from Sat, 10 May 2025 07:00:00 GMT to Sat, 17 Jan 2026 12:33:08 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
